Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

73 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Circulating Cell-Free DNA and Circulating Tumor Cells as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Chemotherapy.
Coco S, Alama A, Vanni I, Fontana V, Genova C, Dal Bello MG, Truini A, Rijavec E, Biello F, Sini C, Burrafato G, Maggioni C, Barletta G, Grossi F. Coco S, et al. Among authors: maggioni c. Int J Mol Sci. 2017 May 11;18(5):1035. doi: 10.3390/ijms18051035. Int J Mol Sci. 2017. PMID: 28492516 Free PMC article.
The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients.
Dal Bello MG, Filiberti RA, Alama A, Orengo AM, Mussap M, Coco S, Vanni I, Boccardo S, Rijavec E, Genova C, Biello F, Barletta G, Rossi G, Tagliamento M, Maggioni C, Grossi F. Dal Bello MG, et al. Among authors: maggioni c. J Transl Med. 2019 Mar 8;17(1):74. doi: 10.1186/s12967-019-1828-0. J Transl Med. 2019. PMID: 30849967 Free PMC article.
Belagenpumatucel-L for the treatment of non-small cell lung cancer.
Rijavec E, Biello F, Genova C, Barletta G, Maggioni C, Dal Bello MG, Coco S, Truini A, Vanni I, Alama A, Beltramini S, Grassi MA, Boccardo F, Grossi F. Rijavec E, et al. Among authors: maggioni c. Expert Opin Biol Ther. 2015;15(9):1371-9. doi: 10.1517/14712598.2015.1073709. Epub 2015 Jul 27. Expert Opin Biol Ther. 2015. PMID: 26211534 Review.
Advances in treatment of mesothelioma.
Maggioni C, Barletta G, Rijavec E, Biello F, Gualco E, Grossi F. Maggioni C, et al. Expert Opin Pharmacother. 2016 Jun;17(9):1197-205. doi: 10.1080/14656566.2016.1176145. Epub 2016 Apr 21. Expert Opin Pharmacother. 2016. PMID: 27055148 Review.
Osimertinib beyond disease progression in T790M EGFR-positive NSCLC patients: a multicenter study of clinicians' attitudes.
Cortellini A, Leonetti A, Catino A, Pizzutillo P, Ricciuti B, De Giglio A, Chiari R, Bordi P, Santini D, Giusti R, De Tursi M, Brocco D, Zoratto F, Rastelli F, Citarella F, Russano M, Filetti M, Marchetti P, Berardi R, Torniai M, Cortinovis D, Sala E, Maggioni C, Follador A, Macerelli M, Nigro O, Tuzi A, Iacono D, Migliorino MR, Banna G, Porzio G, Cannita K, Ferrara MG, Bria E, Galetta D, Ficorella C, Tiseo M. Cortellini A, et al. Among authors: maggioni c. Clin Transl Oncol. 2020 Jun;22(6):844-851. doi: 10.1007/s12094-019-02193-w. Epub 2019 Aug 7. Clin Transl Oncol. 2020. PMID: 31392645
Immunomodulatory effects of metronomic vinorelbine (mVRL), with or without metronomic capecitabine (mCAPE), in hormone receptor positive (HR+)/HER2-negative metastatic breast cancer (MBC) patients: final results of the exploratory phase 2 Victor-5 study.
Pepe FF, Cazzaniga ME, Baroni S, Riva F, Cicchiello F, Capici S, Cogliati V, Maggioni C, Cordani N, Cerrito MG, Malandrin S. Pepe FF, et al. Among authors: maggioni c. BMC Cancer. 2022 Sep 6;22(1):956. doi: 10.1186/s12885-022-10031-6. BMC Cancer. 2022. PMID: 36068484 Free PMC article. Clinical Trial.
73 results